Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

16S Analysis of Parkinsonian Mouse Model Treated with Medications

ABSTRACT: Effect of PD Medication on Mouse Model

PROVIDER: PRJEB66234 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	ERR12066700.fastq.gz	Fastqsanger.gz
	ERR12066800.fastq.gz	Fastqsanger.gz
	ERR12066701.fastq.gz	Fastqsanger.gz
	ERR12066801.fastq.gz	Fastqsanger.gz
	ERR12066702.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 189

Similar Datasets

Whole Exome Sequencing of cohorts of Mutant Braf mouse model melanoma DNA and germline DNA.

Project description:Whole Exome Sequencing of cohorts of Mutant Braf mouse model melanoma DNA and germline DNA. The cohorts are (1) Mutant Braf mouse model melanomas, (2) Mutant Braf mouse model melanomas from UVR exposed mice and (3) Mutant Braf mouse model melanomas from UVR exposed, sunscreen protected mice.

| EGAS00001000729 | EGA

HFpEF model heart failure mouse treated with traditional herbal medicine Goreisan

Project description:In this project we aimed to investigate the effect of Goreisan (GRS, traditional herbal medicine) on HFpEF model heart failure mouse. HFpEF was induced by administration of high-fat diet (HFD)and N-nitro-L-arginine methyl ester (L-NAME), with or without GRS. Mouse heart proteome was analyzed with LC/MS/MS.

2025-09-02 | PXD049259 | JPOST Repository

WGBS of control and DAC-treated tumor tissue from PDX model

Project description:PD-1 blockade has demonstrated impressive clinical outcomes in colorectal cancers that have high microsatellite instability. However, the therapeutic efficacy for patients with tumors with low microsatellite instability or stable microsatellites needs further improvement. Here, we have demonstrated that low-dose decitabine could increase the expression of immune-related genes such as major histocompatibility complex genes and cytokine-related genes as well as the number of lymphocytes at the tumor site in CT26 colorectal cancer-bearing mice. A more significant inhibition of tumor growth and a prolongation of survival were observed in the CT26 mouse model after treatment with a combination of PD-1 blockade and decitabine than in mice treated with decitabine or PD-1 blockade alone. The anti-tumor effect of the PD-1 blockade was enhanced by low-dose decitabine. The results of RNA sequencing and whole-genome bisulfite sequencing of decitabine-treated CT26 cells and tumor samples with microsatellite stability from the patient tumor-derived xenograft model have shown that many immune-related genes, including antigen processing and antigen-presenting genes, were upregulated, whereas the promoter demethylation was downregulated after decitabine exposure. Therefore, decitabine-based tumor microenvironment re-modulation could improve the effect of the PD-1 blockade. The application of decitabine in PD-1 blockade-based immunotherapy may elicit more potent immune responses, which can provide clinical benefits to the colorectal cancer patients with low microsatellite instability or stable microsatellites.

2022-01-03 | GSE192833 | GEO

CTLA-4-Ig internalizes CD80 in fibroblast-like synoviocytes from chronic inflammatory arthritis mouse modelinflammatory arthritis mouse model

Project description:In this study, the therapeutic effect of CTLA-4-Ig in a mouse model of rheumtaoid arthritis, in which CD80 is expressed in chondrocytes and the synovial cells of joints. The therapeutic effect of CTLA-4-Ig appears to extend beyond the lymph nodes into the inflamed synovial compartment through the synergistic inactivation of T cells by the CD80 and PD-L1 axes.

2022-06-19 | GSE200403 | GEO

Single-cell mRNA sequencing of anti-PD-1 GITR-L bispecific antibody treated CT26 mouse tumor model infiltrating leukocytes

Project description:Single-cell mRNA sequencing of anti-PD-1 GITR-L bispecific antibody treated CT26 mouse tumor model infiltrating leukocytes

2021-12-20 | GSE190105 | GEO

RNA sequencing of control and DAC-treated tumor tissue from PDX model

2022-01-03 | GSE192743 | GEO

Chemo-immonotherapeutic effects of PD-L1-targeted antibody-catalyst conjugate plus DOX prodrug in a mouse model of colon cancer

Project description:We designed a study to investiagate chemo-immunotheraputic effect using a mouse model of colon cancer. To investigate the anti-tumor effect of the combination therapy, the in vivo antitumor activities of different mono- and combinational therapy were subsequently evaluated using a C57BL/6J mouse model bearing MC38 tumors. Subcutaneous injection of 1×106 of MC38 cells in the right flank of a mouse was performed 9 days before therapy. The Ru-PD-L1 was administrated by intraperitoneal injection, while the DPD or DOX was given by peritumoral injection. For combinational treatment, each mouse was treated with 14 µg DPD or DOX (0.56 mg/kg) 6 hours after administering 20 ug Ru-PD-L1 (0.80mg/kg). For monotherapy, each mouse was treated with Ru-PD-L1, DPD, or DOX alone. On the 20th day, the mice were sacrificed for tumor collection. The results highlighted that the combination of ACC and DOX prodrug synergistically enhanced immune response and higher antitumor activity compared to the ACC and DOX combination.

2023-05-31 | GSE208721 | GEO

MC903 / Calcipotriol mouse model treated with GLPG2534 or dexamethasone

Project description:The goal of the experiment is to assess the effect of GLPG2534 and dexamethasone in the MC903 mouse model for atopic dermatitis in a therapeutic setting.

2023-01-15 | E-MTAB-10015 | biostudies-arrayexpress

Mouse model of Heptablastoma

Project description:Mouse model of Heptablastoma

| PRJNA798919 | ENA

Mouse model of steatohepatitis

Project description:Mouse model of steatohepatitis

| PRJNA1240229 | ENA